3 months supply of tirzepatide (Month 1) 2.5mg Tirzepatide supply for 3 months

Storr JM, Burton AF

The scientists found that between 2017 and 2022: Average total payments per patient increased 157% among adults without diabetes and 36% among those with diabetes Despite rising total payments, average out-of-pocket payments per patient declined 26% among adults without diabetes and 39% among those with diabetes GLP-1 use increased 643% among adults without diabetes and 230% among adults with diabetes Semaglutide became the dominant GLP-1 drug by 2022, accounting for 54% of usage among adults with diabetes and 65% among adults without diabetes The authors note that while this study only used data through 2022, Medicare and Medicaid spending on GLP-1s has continued to surge in recent years

doi: 10.1007/s00125-019-4963-5 16 GaribayDLouJ.LeeSAZaborskaKEWeissmanMHSlomaEet al

Our compounded version pairs it with B12 to support energy levels during weight loss